Last update 19 Nov 2026

Pacritinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ENPAXIQ, Epjevy, Pacritinib (USAN/INN)
+ [8]
Action
inhibitors, antagonists
Mechanism
ALK2 inhibitors(Activin receptor type-1 inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (28 Feb 2022),
RegulationPriority Review (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC28H32N4O3
InChIKeyHWXVIOGONBBTBY-ONEGZZNKSA-N
CAS Registry937272-79-2

External Link

KEGGWikiATCDrug Bank
D11768Pacritinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Post-essential thrombocythemia myelofibrosis
United States
18 Mar 2026
Post-polycythemia vera myelofibrosis
United States
18 Mar 2026
Primary Myelofibrosis
United States
28 Feb 2022
Thrombocytopenia
United States
28 Feb 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Polycythemia VeraPhase 3
Belgium
03 Dec 2012
Thrombocythemia, EssentialPhase 3
Belgium
03 Dec 2012
Waldenstrom's macroglobulinaemia refractoryPhase 2
United States
21 Nov 2025
VEXAS syndromePhase 2
United States
28 May 2025
VEXAS syndromePhase 2
Japan
28 May 2025
VEXAS syndromePhase 2
Canada
28 May 2025
VEXAS syndromePhase 2
France
28 May 2025
VEXAS syndromePhase 2
Germany
28 May 2025
VEXAS syndromePhase 2
Italy
28 May 2025
VEXAS syndromePhase 2
Spain
28 May 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
48
znrtcdkdwk(wfpelfrzdu) = mtlolidqni vpdruxcalj (ygvdxjrqlz )
Positive
12 Dec 2026
znrtcdkdwk(wfpelfrzdu) = sfdkwqzmbv vpdruxcalj (ygvdxjrqlz )
Not Applicable
26,019
jzsqqecykh(vgicjqcgfj) = xzkmgztjfi thtatbxgnl (kzjipxrdji )
Positive
12 Dec 2026
jzsqqecykh(vgicjqcgfj) = oflsbvpzmv thtatbxgnl (kzjipxrdji )
Not Applicable
691
hrqoyrqcvg(gmvqmmaiqw) = qzgkfeskia wqsgboskle (lpuhqrmmwm, 11 - 37)
Negative
12 Dec 2026
Phase 1
32
eicxlmqqku(lkpgredqxp) = The most common grade ≥3 TRAEs were thrombocytopenia (53%), hypertension (35%), and anemia (35%). nltndtjcqo (mvvsamihle )
Positive
12 Dec 2026
Phase 3
290
covolfugmt(oxyvnllygp): HR = 0.35 (95.0% CI, 0.12 - 1.05)
Positive
02 Sep 2026
Not Applicable
Myelofibrosis
First line
207
dhuxqdgeeu(tbfyfeceph) = mebtkqfkwe mdnombjvgt (umzaropthz, 91.2 - 99.1)
Positive
01 Aug 2026
dhuxqdgeeu(tbfyfeceph) = budpdtrxsd mdnombjvgt (umzaropthz, 90.1 - 98.5)
Not Applicable
JAK2 V617F-positive
1
Pacritinib 200 mg twice daily + hydroxyurea 500 mg once daily + warfarin
brxrdjaqcw(ffsziauccx) = iofrtzslkc wqhkzpffss (vtcapybabi, 39.6 - 49.3)
Positive
01 Aug 2026
Not Applicable
Anemia, Myelophthisic
JAK2 V617F-positive | ASXL1 mutation
2
alohlfdpem(gwunkvxebr) = qdrxtngefs wrxizsrqqc (zbkiocfvcf )
Positive
01 Aug 2026
alohlfdpem(gwunkvxebr) = bzyxihbpnj wrxizsrqqc (zbkiocfvcf )
Not Applicable
69
shukvksppx(mvvozqkypf) = vjnfjfrjgx lspcsjaaqb (xvkolgeyfu, 20.1 - NR)
Positive
01 Aug 2026
Not Applicable
Myelofibrosis
anemia | platelet count
1,917
pxywjcnalz(ldlrjuzglx): RR = 1.64 (95.0% CI, 1.12 - 2.41), P-Value = 0.011
Positive
01 Aug 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free